This study is trying to evaluate the efficacy and safety of modified DEP regimens for the treatment of active hemophagocytic lymphohistiocytosis.
According to the HLH-2004 criteria, the patient meets the HLH diagnosis.
1 year old < age < 70 years old, regardless of gender.
Before the start of the study, total bilirubin ≤ 10 times the upper limit of normal; serum creatinine ≤ 1.5 times the normal value; fibrinogen can be corrected to ≥ 0.6g/L after infusion.
Allergic to liposome doxorubicin, etoposide, and ruxolitinib or with severe allergic constitution;
Severe myocardial damage, with myocardial enzyme CK and CK-MB increased more than 3 times ULN (upper limit of normal value).
Patients with heart disease of grade II or above (including grade II) according to the New York Heart Association (NYHA) score.
Subjects who have used a total cumulative dose of doxorubicin ≥300mg/m2 or a total cumulative dose of epirubicin ≥450mg/m2, or who have previously used anthracyclines to cause heart disease.